VOLIXIBAT NCT02787304


Laboratory : SHIRE

Study Name : 

Phase 2

Study Number : NCT02787304

Number of patients recruited : 266

Probability to be under placebo : 25%

Contacts : 

Contact: Shire Call Contact

clinicaltransparency@shire.com








Share on StockTwits

WWW.NASHBIOTECHS.COM  -  Copyright G DIVRY 2015-2016